biogen inc american multinational biotechnology company based cambridge massachusetts united states specializing discovery development delivery therapies treatment neurological diseases patients worldwide biogen operates argentina brazil canada china france germany hungary india italy japan mexico netherlands poland sweden biogen founded geneva biotechnology geneva several prominent biologists including kenneth murray university edinburgh phillip allen sharp massachusetts institute technology walter gilbert harvard university gilbert served ceo startup phase biogen heinz schaller university heidelberg charles weissmann university zurich weissmann contributed first product interferon gilbert sharp subsequently honored nobel prizes gilbert recognized nobel prize chemistry understanding dna sequencing sharp received nobel prize physiology medicine discovery split genescitation needed biogen merged san diego californiabased idec pharmaceuticals formed university californiasan diegos physicians immunologists ivor royston robert e sobol san diego bio entrepreneur howard birndorf stanford university cancer researchers ron levy richard miller adopted name biogen merger biogen idec became largest biotechnology company following shifts research core areas company since shortened name reverting simply biogen stock component several stock indices sp sp company listed nasdaq stock exchange ticker symbol may company announced would acquire cancer specialist conforma therapeutics later month company announced intention acquire fumapharm ag consolidating ownership fumaderm oral fumarate studied treatment multiple sclerosis january company announced would acquire syntonix pharmaceuticals million gaining syntonixs lead product hemophilia b well technology developing inhalable two new brain infection cases tysabri users surfaced europe raised international concern tysabri effects progressive multifocal leukoencephalopathy pml brain condition biogen one drugs biogen announced drug fampyra received conditional marketing approval conditional approval biogen agrees provide additional data longterm benefits safety december biogen announced global collaboration agreement isis pharmaceuticals develop research antisense drugs treat neurological neuromuscular february bloomberg broke news biogen planning pay elan billion full rights tysabri used treat multiple january company announced would acquire convergence pharmaceuticals million acquisition aiming accelerate development convergences pipeline particular phase ii small molecule sodium channel blocking october company announced would lay workforce effective may biogen announced spin hemophilia business known bioverativ hemophilia business would become independent publicly traded company bioverativ offered two hemophilia drugs alprolix eloctate plans developing hemophiliafocused biogen released spinraza nusersin treatment spinal muscular atrophy drug among expensive treatments available price first year doses subsequent year likely rest patients still isnt cure spinraza significantly improves quality life infants adults biogen announced drug fampyra converted conditional marketing authorization standard marketing approval eu multiple sclerosis ms patients use fampyra improve february biogen sangamo therapeutics announced global licensing deal develop compounds neuromuscular neurological september biogen inc made million deposit oneunited bank provide capital fund home loans commercial development black november company announced would acquire million stake cambridgebased sage therapeutics make upfront payment million order jointly develop number depression july announced biogen acquired plano texasheadquartered biotech company reata pharmaceuticals nearly company reached licensing agreement neurimmune spinoff university zurich alzheimers disease drug aducanumab developed swiss company later neurimmune sold rights license fees million december biogen announced aducanumab drug alzheimers treatment preparing go latestage trial experimental alzheimers disease treatment medication dramatically improved cognition reduced brain plaque levels earlystage march biogens aducanumab drug alzheimers treatment becomes first experimental alzheimers treatment show significant results regard slowing cognitive decline reducing braindestroying july biogen initiates two latestage studies called engage emerge assess aducanumab adults early alzheimers biogens aducanumab decreases amoyloidbeta brains people earlystage alzheimers disease according report published nature august march biogen announced phase clinical trials aducanumab march biogen announced would acquire nightstar therapeutics per share million total nightstar focus adenoassociated virus based genetherapies inherited retinal setback alzheimers drug research march biogens shares fell ended trial drug aducanumab making along october however announced would pursue fda approval aducanumab together october despite two phase clinical trials previously halted futility biogen announced plan submit fdas approval may biogen wrapped construction stateoftheart facility solothurn switzerland produce alzheimers drug aducanumab late alongside north carolina manufacturing facility monoclonal antibody codeveloped eisai attracted considerable interest biotech investors warren buffetts berkshire hathaway bought biogen shares combined value july biogen eisai announced companies together successfully submitted aducanumabs fda regulatory marketing june fda gave accelerated approval aducanumab name proved drug priced us dollars per year covered many insurers wait proof drug also us government subsidise outside clinical according food treatment administrations website drug proven reduce amyloidbeta plaques brain likely benefit patients fda stated postapproval trial indicate aduhelm works drug may taken may company announced would spin hemophilia drug business eloctate alprolix public august company announced spun company would called bioverativ order show heritage company would trade nasdaq exchange ticker symbol would look spun early bioverativ acquired sanofi following illustration companys major mergers acquisitions historical predecessors comprehensive list march biogen reported three individuals met employees conference boston tested positive previous march public health officials reported five new cases associated biogen leadership march massachusetts health officials announced new presumptive cases connected biogen researchers first estimated conference would linked states coronavirus researchers later estimated cases worldwide caused biogen conference including us cases fiscal year biogen reported earnings billion annual revenue billion increase previous fiscal cycle biogens shares traded per share market capitalization valued billion november company ranked fortune list largest united states corporations biogen japanese eisai collaborators development commercialization biogen swedish orphan biovitrum sobi collaborators development commercialization commercialized united states ampyra dalfampridine extended release tablets acorda acquired acquisition fumapharm ag currently commercialized united states genentech wholly owned subsidiary antitnf refractory rheumatoid arthritis ancaassociated vasculitis chronic lymphocytic leukemia currently commercialized roche subsidiary genentech biogen focused rd efforts discovery development treatments patients high unmet medical needs areas neurology hematology immunologycitation needed investigational ms medicines biogen several candidates phase clinical trials neurodegenerative immunological diseases including ms neuropathic pain spinal muscular atrophy lupus nephritis biogen also several development agreements place ionis pharmaceuticals collaborate leverage antisense technology advancing treatment neurological february biogen formalized joint venture samsung creating samsung bioepis joint venture brings biogens expertise capabilities protein engineering cell line development recombinant biologics manufacturing position joint venture biogen participate emerging market early biogen entered agreement eisai inc jointly develop commercialize two candidates alzheimers disease potential reduce aÎ² plaques form brains patients well slow formation new plaques potentially improving symptoms suppressing disease biogen also since agreement agtc develop gene therapy several genetic diseases including xlinked retinoschisis xlrs xlinked retinitis pigmentosa xlrp ophthalmologic diseases aim biogen paid agtc million including equity investment million billion future march biogen halted phase trials alzheimers disease drug aducanumab independent groups analysis showed trials unlikely meet primary however october reversed plans said would pursuing us fda approval aducanumab reversal came biogen said new analysis larger patient pool showed promising july biogen completed submission biologics license application bla fda review requested accelerated however advisory panel fda voted approval june fda granted approval aducanumab treatment alzheimers disease aducanumab approved using accelerated approval pathway biogen required conduct postapproval clinical trial verify clinical benefit continued september biogen agreed pay million us federal governments states whistleblower accused company paying kickbacks doctors increase prescriptions avonex tysabri tecfidera multiple httpsenwikipediaorgwikiidecpharmaceuticals